ORCA
Online Research @ CardiffÂ
Browse by Current Cardiff authors
![[up]](/style/images/multi_up.png)
Up a levelNumber of items: 8.
Russell, Nigel H., Thomas, Abin  ORCID: https://orcid.org/0000-0002-8283-6762, Hills, Robert K., Thomas, Ian, Gilkes, Amanda, Marquez Almuina, Nuria, Burns, Sarah, Marsh, Lucy, Vyas, Paresh, Metzner, Marlen, McCarthy, Nicholas, Andrew, Georgia, Byrne, Jennifer, Sellar, Rob S., Kelly, Richard, Cahalin, Paul, Malthe Overgaard, Ulrik, Mehta, Priyanka, Dennis, Mike, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441 and Freeman, Sylvie D.
2024.
Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial.
Journal of Clinical Oncology
10.1200/JCO.24.00259
|
|
|
|
Freeman, Sylvie D, Thomas, Abin, Thomas, Ian, Vyas, Paresh, Gilkes, Amanda, Metzner, Marlen, Jakobsen, Niels Asger, Kennedy, Alison, Moore, Amy, Marquez Almuina, Nuria, Burns, Sarah, King, Sophie, Andrew, Georgia M., Gallagher, Kathleen M.E., Sellar, Rob, Cahalin, Paul, Weber, Duruta, Dennis, Mike, Mehta, Priyanka, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441 and Russell, Nigel H.
2022.
A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results.
Blood
140
(S1)
, pp. 532-533.
10.1182/blood-2022-162245
|
|
|
Hole, Paul Spencer, Zabkiewicz, Joanna ORCID: https://orcid.org/0000-0003-0951-3825, Munje, Chinmay, Newton, Zarabeth, Pearn, Lorna, White, Paul Charles ORCID: https://orcid.org/0000-0002-6562-4696, Marquez, Nuria, Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Burnett, Alan Kenneth, Tonks, Alex ORCID: https://orcid.org/0000-0002-6073-4976 and Darley, Richard Lawrence ORCID: https://orcid.org/0000-0003-0879-0724
2013.
Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling.
Blood
122
(19)
, pp. 3322-3330.
10.1182/blood-2013-04-491944
|
|
|
|
Errington, Rachel Jane ORCID: https://orcid.org/0000-0002-8016-4376, Chappell, Sally Claire, Khan, Imtiaz A., Marquez Almuina, Nuria, Wiltshire, Marie, Griesdoorn, Victoria D. and Smith, Paul James
2013.
Time-lapse microscopy approaches to track cell cycle and lineage progression at the single-cell level.
Current Protocols in Cytometry
64
(12.4)
10.1002/0471142956.cy1204s64
|
|
|
|
Tiffen, P., Omidvar, Nader, Marquez, Nuria, Croston, D., Watson, C. and Clarkson, Richard W. E. ORCID: https://orcid.org/0000-0001-7389-8673
2008.
A dual role for Oncostatin M signalling in the differentiation and death of mammary epithelial cells in vivo.
Molecular Endocrinology
22
(12)
, pp. 2677-2688.
10.1210/me.2008-0097
|
|
|
|
Smith, Paul James, Marquez, Nuria, Wiltshire, Marie, Chappell, Sally Claire, Njoh, Kerenza, Campbell, Lee, Khan, Imtiaz Ali, Silvestre, Oscar and Errington, Rachel Jane ORCID: https://orcid.org/0000-0002-8016-4376
2007.
Mitotic bypass via an occult cell cycle phase following DNA topoisomerase II inhibition in p53 functional human tumor cells.
Cell Cycle
6
(16)
, pp. 2071-2081.
10.4161/cc.6.16.4585
|
|
|
|
Marquez, Nuria, Chappell, Sally Claire, Sansom, Owen J. ORCID: https://orcid.org/0000-0001-9540-3010, Clarke, Alan Richard ORCID: https://orcid.org/0000-0002-4281-426X, Teesdale-Spittle, Paul, Errington, Rachel Jane ORCID: https://orcid.org/0000-0002-8016-4376 and Smith, Paul James
2004.
Microtubule stress modifies intra-nuclear location of Msh2 in mouse embryonic fibroblasts.
Cell Cycle
3
, pp. 662-671.
|
|
|
|
Marquez, Nuria, Chappell, Sally Claire, Sansom, Owen J. ORCID: https://orcid.org/0000-0001-9540-3010, Clarke, Alan Richard ORCID: https://orcid.org/0000-0002-4281-426X, Errington, Rachel Jane ORCID: https://orcid.org/0000-0002-8016-4376, Smith, Paul James and Court, Jonathan
2003.
Single cell tracking reveals that Msh2 is a key component of an early-acting DNA damage-activated G2 checkpoint.
Oncogene
22
(48)
, pp. 7642-7648.
10.1038/sj.onc.1206876
|
|
|